$-0.06 EPS Expected for Catalyst Pharmaceuticals, Inc. (CPRX); Teledyne Tech (TDY) Shorts Down By 7.87%

February 15, 2018 - By Vivian Currie

Teledyne Tech Incorporated (NYSE:TDY) had a decrease of 7.87% in short interest. TDY’s SI was 614,300 shares in February as released by FINRA. Its down 7.87% from 666,800 shares previously. With 104,800 avg volume, 6 days are for Teledyne Tech Incorporated (NYSE:TDY)’s short sellers to cover TDY’s short positions. The SI to Teledyne Tech Incorporated’s float is 1.77%. The stock increased 2.21% or $4.03 during the last trading session, reaching $186.28. About 147,586 shares traded. Teledyne Technologies Incorporated (NYSE:TDY) has risen 37.51% since February 15, 2017 and is uptrending. It has outperformed by 20.81% the S&P500.

Analysts expect Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report $-0.06 EPS on March, 21.They anticipate $0.01 EPS change or 20.00% from last quarter’s $-0.05 EPS. After having $-0.05 EPS previously, Catalyst Pharmaceuticals, Inc.’s analysts see 20.00% EPS growth. The stock increased 0.86% or $0.03 during the last trading session, reaching $3.5. About 5,720 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 267.48% since February 15, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $358.66 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder.

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 13 analyst reports since April 26, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 1 by Roth Capital. The rating was maintained by SunTrust on Monday, November 27 with “Buy”. Roth Capital maintained it with “Buy” rating and $4.7500 target in Thursday, August 10 report. The firm has “Overweight” rating given on Wednesday, October 5 by Piper Jaffray. SunTrust maintained it with “Buy” rating and $5.0 target in Friday, September 1 report. The stock has “Neutral” rating by Piper Jaffray on Tuesday, April 26. The firm has “Buy” rating by Piper Jaffray given on Friday, December 1. The firm has “Buy” rating by SunTrust given on Tuesday, October 31. On Friday, November 10 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Overweight” rating given on Wednesday, October 5 by PiperJaffray.

Investors sentiment decreased to 2 in 2017 Q3. Its down 0.22, from 2.22 in 2017Q2. It turned negative, as 3 investors sold Catalyst Pharmaceuticals, Inc. shares while 15 reduced holdings. 17 funds opened positions while 19 raised stakes. 34.72 million shares or 4.30% more from 33.29 million shares in 2017Q2 were reported. California Pub Employees Retirement invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). California State Teachers Retirement Sys stated it has 117,600 shares. Vanguard Group Inc has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 3.04M shares. Royal Bank & Trust Of Canada holds 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 171,487 shares. Consonance Limited Partnership reported 0.1% stake. Schwab Charles Investment Mngmt Incorporated has 120,500 shares for 0% of their portfolio. Wells Fargo Mn invested 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). 11,480 are owned by Two Sigma Lc. Geode Capital Mngmt Limited Company reported 627,212 shares. Goldman Sachs Group has 45,568 shares for 0% of their portfolio. First Allied Advisory Services reported 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Vantage Investment Advsrs Limited Liability Company accumulated 0% or 3,000 shares. Ajo Limited Partnership invested in 766,233 shares or 0.01% of the stock. Cwm Ltd Liability Com stated it has 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Kennedy Capital holds 0.04% or 900,618 shares in its portfolio.

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.03, from 1.31 in 2017Q2. It turned negative, as 27 investors sold Teledyne Technologies Incorporated shares while 68 reduced holdings. 39 funds opened positions while 83 raised stakes. 29.58 million shares or 1.93% more from 29.02 million shares in 2017Q2 were reported. Louisiana State Employees Retirement Sys holds 0.07% or 9,400 shares. Advisory Ser Ntwk Llc holds 0% of its portfolio in Teledyne Technologies Incorporated (NYSE:TDY) for 123 shares. Kayne Anderson Rudnick Invest Limited Liability Company invested 1.54% of its portfolio in Teledyne Technologies Incorporated (NYSE:TDY). Moreover, Weaver C Barksdale & has 0.01% invested in Teledyne Technologies Incorporated (NYSE:TDY). Susquehanna Llp invested 0% in Teledyne Technologies Incorporated (NYSE:TDY). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% of its portfolio in Teledyne Technologies Incorporated (NYSE:TDY). Comerica National Bank & Trust reported 36,436 shares. Quantitative Systematic Strategies Limited Liability reported 0.18% of its portfolio in Teledyne Technologies Incorporated (NYSE:TDY). Scopus Asset Management Lp invested 0.01% in Teledyne Technologies Incorporated (NYSE:TDY). Hirtle Callaghan & Llc has invested 0.7% in Teledyne Technologies Incorporated (NYSE:TDY). Moreover, Advantus Mngmt has 0.02% invested in Teledyne Technologies Incorporated (NYSE:TDY). Northwestern Mutual Wealth Mgmt Comm, a Wisconsin-based fund reported 62 shares. Northern Tru holds 0.01% or 286,107 shares in its portfolio. Bank & Trust Of America Corp De reported 296,691 shares stake. Oppenheimer & Commerce Inc reported 3,736 shares or 0.02% of all its holdings.

Teledyne Technologies Incorporated provides instrumentation, digital imaging, aerospace and defense electronics, and engineered systems in the United States, Canada, the United Kingdom, and internationally. The company has market cap of $6.60 billion. The companyÂ’s Instrumentation segment offers monitoring and control instruments for marine, environmental, industrial, and other applications, as well as electronic test and measurement equipment; and power and communications connectivity devices for distributed instrumentation systems and sensor networks deployed in mission critical and harsh environments. It has a 29.76 P/E ratio. The Company’s Digital Imaging segment provides image sensors and digital cameras for use in industrial, scientific, medical, and photogrammetry applications; and hardware and software for image processing in industrial and medical applications, as well as manufacturing services for micro electro-mechanical systems.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>